% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

techfan20 12 posts  |  Last Activity: Apr 24, 2015 7:16 AM Member since: Dec 10, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by yappy_mutt Apr 22, 2015 12:22 PM
    techfan20 techfan20 Apr 24, 2015 7:16 AM Flag

    I also expect sales growth of Grafix commensurate with in scale of the investment in an expanded salesteam and Lode's statements about expected productivity of an expanded salesforce. It is way too early in the game to be approaching product maturity. If this isnt occurring, I imagine serious questions from Peter.

  • Reply to

    q1 revenue

    by soncnivzhod Apr 15, 2015 4:23 AM
    techfan20 techfan20 Apr 15, 2015 7:05 AM Flag

    I expect more sales growth than that from the expanded sales team. Based on Lode's prior comments, he does too.

    Sentiment: Strong Buy

  • NEW YORK and MELBOURNE, Australia, March 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (MBLTY) today announced that it has been selected by the Japan External Trade Organization (JETRO) as the only regenerative medicine company worldwide to receive fast track access to potential investment incentives across all levels of government in Japan. Mesoblast will receive a specially tailored market and government incentive roadmap aimed at providing a more attractive business environment.

    JETRO reviewed thousands of companies worldwide with the capacity to generate large-scale investment and employment in Japan through the establishment of Japanese hubs for research and development, manufacturing, and commercialization. Ten companies across all industries, including Mesoblast, were chosen to receive fast track access to specific incentives and programs.

    JETRO's Oceania Managing Director, Shuichi Hirano, said the JETRO initiative is a direct result of the Japan Revitalization Strategy, created by the Japanese Government in 2013, that placed the activation of foreign direct investment as an important economic policy and set a goal of doubling the current investment balance to 35 trillion yen in 2020.

    "Japan is focused on becoming a dominant force in the regenerative medicine industry, which we believe holds great prospects to stimulate revenue and employment in Japan, as well as providing novel and cost-efficient solutions for patients with distinct, unmet medical needs," Mr Hirano said.

    Mesoblast Chief Executive Silviu Itescu welcomed the recognition from the Japanese Government. "Japan is a major market for our cell-based therapeutics and offers near-term potential for product approvals and revenues. The selection of Mesoblast by JETRO as the only regenerative medicine company to receive investment priority status will guide the strategic direction of our commercial plans in Japan, in conjunction with our current and future strategic partners."

  • Reply to

    Cartiform, How Big

    by ozark580 Mar 2, 2015 7:26 AM
    techfan20 techfan20 Mar 2, 2015 7:05 PM Flag

    Cartiform is a vast improvement of the standard of care. Minimally invasive surgical procedures broaden the application. Global demand will cap it off. Lots of biomechanical issues in the various joints of the body. Arthrex wouldn't have signed on if they didn't think it a winner.

    Sentiment: Strong Buy

  • Reply to

    Employee Count

    by the_stakeholder Mar 2, 2015 10:48 AM
    techfan20 techfan20 Mar 2, 2015 11:37 AM Flag

    On the conference call, Lode said they were building a direct sales force for Grafix, so yes this would be to talk with practitioners and medical facilities.
    They also stated that inventory and production was being built up before making a national sales push in 2015. They further stated that plant capacity would run out later this year necessitating expansion of manufacturing capacity.

    Sentiment: Strong Buy

  • Reply to

    Ain't Selling

    by tjed78217 Mar 2, 2015 10:31 AM
    techfan20 techfan20 Mar 2, 2015 11:14 AM Flag

    I concur, I fully expect actuals to crush analyst estimates.

    Sentiment: Strong Buy

  • Reply to

    Employee Count

    by the_stakeholder Mar 2, 2015 10:48 AM
    techfan20 techfan20 Mar 2, 2015 11:13 AM Flag

    On the conference calls Lode D discussed building a direct sales force for Grafix, this would be the 106. On the Osiris career site we have seen job openings for production, shipping, globalization, and compliance listed - those types of positions gets the numbers from 106 to 125.

    Sentiment: Strong Buy

  • From cnbc website (today)

    The "Mad Money" host said that many hedge funds and brokerage research houses use different third-party information services in order to predict the health of a company and the direction of the stock.

    The problem with these sampling services, according to Cramer, is that they have frequently underestimated sales and produced inaccurate results. Thus, the moves in both Skechers and Columbia last week were a result of hedge funds' desperately reaching for a stock to cover their short sales that were created due to faulty information.

    Sentiment: Strong Buy

  • Reply to

    CC Questions per ch47ady suggestion

    by ozark580 Feb 16, 2015 3:43 PM
    techfan20 techfan20 Feb 16, 2015 6:51 PM Flag

    Oz, you undercounted. If Osiris does this too, it will still be a bigger number than the analysts estimate...ha!

    The question I would ask is, has/will Osiris talked with local/state governmental officials about economic development incentives before they expand manufacturing in the current location? States are competing to recruit and retain economic engines.

    Sentiment: Strong Buy

    New York, USA, and Melbourne, Australia; 10 February 2015: Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the United States Patent and Trademark Office (USPTO) covering its proprietary Mesenchymal Precursor Cell (MPC) technology for use in the treatment of degenerated intervertebral discs. Granted US patent number 8,858,932 provides Mesoblast with exclusive commercial rights through to June 2029. There is also potential for patent term and regulatory exclusivity extensions which would provide longer term protection.

    This latest granted patent is one of a suite of patents that provides Mesoblast with multiple layers of protection for its product candidates in the treatment of low back pain due to degenerating discs. United States patents have already been granted covering Mesoblast's product candidates for repair and regeneration of intervertebral discs and for spinal fusion, including product compositions (US 7122178 and US 8158118), and methods of use (US 7670628 and US 8062675). Mesoblast also has several pending applications which will be used to pursue additional claims to broaden and extend protection for its product candidates for the treatment of chronic low back pain.

  • techfan20 by techfan20 Jan 29, 2015 8:59 PM Flag

    Osiris has conquered regenerative medicine in terms of skin, cartilage, and bone. They clearly have proven the ability to innovative, bring products to market, scale operations, and align with strategic partners. So what is next?

    I really don't know, but maybe Osiris' expertise extends to tendons? osteoarthritis? hair growth? Folks in this space are already looking at such things. Lots of possibilities.

    Sentiment: Strong Buy

  • Reply to

    Pass the paint please...

    by ozark580 Jan 27, 2015 5:16 PM
    techfan20 techfan20 Jan 28, 2015 7:35 AM Flag

    Wow! Global sales is huge!!! This supercharges the Osiris sales engine.

    Peter and Lode and the rest of the osiris team will be hailed as geniuses

    Sentiment: Strong Buy

15.83-0.50(-3.06%)12:27 PMEDT